FINWIRES · TerminalLIVE
FINWIRES

$MPLT

28 stories mentioning MPLTUpdated 38d ago

Every FINWIRES story that references MPLT, newest first.

What are analysts saying about MPLT?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on MPLT?

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks eased late Thursday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) shed 0.8%.In corporate news, Abeona Therapeutics (ABEO) shares fell past 15% after its Q2 results missed analysts' expectations.Monopar Therapeutics (MNPR) shares shed 4.3% after Cantor Fitzgerald downgraded the company's stock to neutral from overweight and adjusted the price target to $119 from $109.Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported. Novartis shares declined 0.3%.MapLight Therapeutics (MPLT) shares climbed 3.8%. The company plans to sell securities in a private-placement financing for gross proceeds of $150 million.

$ABEO$MNPR$MPLT$NVS
Sectors

Sector Update: Healthcare Stocks Softer in Afternoon Trading

Healthcare stocks eased Thursday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each dropping 0.2%.The iShares Biotechnology ETF (IBB) fell 0.6%.In corporate news, Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported. Novartis shares declined 0.2%.MapLight Therapeutics (MPLT) shares climbed 4%. The company plans to sell securities in a private-placement financing for gross proceeds of $150 million.MeiraGTx (MGTX) shares rose 2.6% after the company reported a Q2 profit as revenue soared.Cullinan Therapeutics (CGEM), Taiho Oncology and Taiho Pharmaceutical said a phase 3 trial evaluating the combination of their jointly developed drug zipalertinib and chemotherapy to treat adults with non-small cell lung cancer met its primary endpoint. Cullinan shares rose 2.2%.

$CGEM$MGTX$MPLT$NVS
Wire

MapLight Therapeutics Launching $150 Million Private Placement Financing

MapLight Therapeutics (MPLT) said Thursday it has signed an agreement with investors to sell securities in a private placement financing, for gross proceeds of about $150 million.The company said it is selling nearly 9.2 million shares at $11.38 per share and, in lieu of shares to some investors, pre-funded warrants to buy up to nearly 4 million shares at $11.3799 per pre-funded warrant.The PIPE financing is expected to close on Friday, the company said.MapLight said it will use proceeds from the financing mainly to back the advancement of ML-007C-MA, including funding a phase 2 trial in Alzheimer's disease psychosis, and a phase 3 trial in schizophrenia, as well as for working capital and general corporate purposes.The company said its cash, cash equivalents and investments were $351.3 million as of June 30, which, together with the net proceeds from the PIPE financing, will be enough to fund the advancement of ML-007C-MA through 2028.MapLight shares were up past 4% in early trading.Price: $11.90, Change: $+0.51, Percent Change: +4.53%

$MPLT
Research

UBS Downgrades MapLight Therapeutics to Neutral From Buy, Adjusts PT to $13 From $52

MapLight Therapeutics (MPLT) has an average rating of Buy and mean price target of $32.31, according to analysts polled by FactSet.

$MPLT
Research

Morgan Stanley Downgrades MapLight Therapeutics to Equalweight From Overweight, $34 PT

MapLight Therapeutics (MPLT) has an average rating of Buy and mean price target of $32.31, according to analysts polled by FactSet.

$MPLT
Wire

Top Midday Decliners

MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML-007C-MA in adults with an acute exacerbation of schizophrenia met the primary endpoint at the twice-daily 210/3 mg dose. The once-daily 330/6 mg dose failed to achieve statistical significance on the primary endpoint, showing only numerical improvement over placebo.Intraday volume topped 5.13 million shares, compared with the daily average of 413,234.AiRWA (YYAI) agreed to buy Hongkong Best Life Trade for a base price of $50 million plus potential performance payouts.The stock plunged 74% with volume topping 2.05 million shares, compared with the daily average of 19,642.Nvidia (NVDA) agreed to expand its partnership with South Korean conglomerate SK Group through an AI infrastructure initiative valued at more than $500 billion.Nvidia dropped 5% as volume topped 100.3 million shares, compared with the daily average of 154.5 million.SK hynix (SKHY), part of the SK Group, fell 7.6% as volume topped 40.5 million shares, compared with the daily average of 55.5 million.Price: $11.52, Change: $-25.04, Percent Change: -68.49%

$MPLT$NVDA$SKHY$YYAI
Equities

Top Premarket Decliners

STAK (STAK) shares were down 55% in Monday premarket trading after the earlier session's 602% rally.MapLight Therapeutics (MPLT) stock was down 55% after the company said a phase 2 trial of ML-007C-MA in schizophrenia met its primary endpoint, demonstrating a significant reduction in severity of the condition versus placebo.Profusa (PFSA) shares were down 18% after the company signed a non-binding term sheet to acquire a privately held commercial-stage diagnostics and toxicology testing company.Recon Technology (RCON) stock was down 15%, following the earlier session's 11.6% gain.

$MPLT$PFSA$RCON$STAK
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.4%.The iShares Biotechnology ETF (IBB) climbed 1.3%.In corporate news, Novo Nordisk (NVO) sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish drugmaker's products. Novo shares fell 0.7%, and Lilly rose 1.7%.Danaher (DHR) raised its full-year profit guidance as fiscal Q2 results came in stronger than expected. The company lowered the top end of its 2026 revenue growth outlook, and the shares fell 11%.Okyo Pharma (OKYO) shares rose 5.8%. Chairman Gabriele Cerrone increased his stake in the company to 10.9 million shares, or 20.5% of the issued shares, with the purchase of 25,000 shares at $1.40 each.MapLight Therapeutics (MPLT) is seen having meaningful upside in the ML-007 Phas2 2 schizophrenia trial readout with data expected in mid-August, UBS Securities said. MapLight shares rose 4.1%.

$DHR$LLY$MPLT$NVO$OKYO
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) climbed 1.3%.In corporate news, MapLight Therapeutics (MPLT) is seen having meaningful upside in the upcoming ML-007 Ph2 schizophrenia trial readout, with the study completed on June 4th and data expected in mid-August, UBS said in a note. MapLight shares rose 3%.

$MPLT
Wire

MapLight Therapeutics Seen Having Upside in Schizophrenia Trial Readout, UBS Says

MapLight Therapeutics (MPLT) is seen having meaningful upside in the upcoming ML-007 Ph2 schizophrenia trial readout, with the study completed on June 4th and data expected in mid-August, UBS said in a note Tuesday.The bank said investors are primarily focused on whether ML-007 can demonstrate a clean tolerability profile, with low rates of vomiting and nausea that can differentiate it from Cobenfy.UBS said the potential advantages of once-daily dosing and no food restrictions are particularly important in the schizophrenia patient group given challenges with adherence and cognitive impairment, adding that better tolerability could be a win even with similar efficacy.UBS maintained a buy rating and raised price target to $52 from $48.Price: $37.00, Change: $+1.01, Percent Change: +2.81%

$MPLT
Wire

UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating

MapLight Therapeutics, Inc. (MPLT) has an average rating of Buy and mean price target of $43.23, according to analysts polled by FactSet.Price: $37.06, Change: $+1.07, Percent Change: +2.96%

$MPLT
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $1,345,894, According to a Recent SEC Filing

Anatol Kreitzer, Chief Discovery Officer, on July 15, 2026, sold 36,284 shares in Maplight Therapeutics (MPLT) for $1,345,894. Following the Form 4 filing with the SEC, Kreitzer has control over a total of 174,906 voting common shares of the company, with 174,906 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202123826000010/xslF345X05/form4-07202026_060701.xml

$MPLT
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $1,372,668, According to a Recent SEC Filing

Jonathan Gillis, Chief Accounting Officer and Interim Chief Financial Officer, on July 15, 2026, sold 36,979 shares in Maplight Therapeutics (MPLT) for $1,372,668. Following the Form 4 filing with the SEC, Gillis has control over a total of 144,240 voting common shares of the company, with 144,240 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000170995426000010/xslF345X05/form4-07202026_060704.xml

$MPLT
Insider Trading

MapLight Therapeutics Insider Sold Shares Worth $1,734,490, According to a Recent SEC Filing

Erin Pennock Foff, Chief Medical Officer, on July 15, 2026, sold 47,158 shares in MapLight Therapeutics (MPLT) for $1,734,490. Following the Form 4 filing with the SEC, Foff has control over a total of 298,901 voting common shares of the company, with 298,901 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202123326000012/xslF345X05/form4-07182026_010714.xml

$MPLT
Insider Trading

MapLight Therapeutics Insider Sold Shares Worth $5,443,722, According to a Recent SEC Filing

Christopher A. Kroeger, Director, Chief Executive Officer, on July 15, 2026, sold 147,639 shares in MapLight Therapeutics (MPLT) for $5,443,722. Following the Form 4 filing with the SEC, Kroeger has control over a total of 1,347,645 voting common shares of the company, with 1,246,455 shares held directly and 101,190 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000165891826000014/xslF345X05/form4-07182026_010744.xml

$MPLT
Research

Raymond James Initiates Coverage on MapLight Therapeutics With Strong Buy Rating

MapLight Therapeutics, Inc. (MPLT) has an average rating of Buy and mean price target of $39.55, according to analysts polled by FactSet.

$MPLT
Sectors

Sector Update: Healthcare Stocks Flat to Lower Premarket Monday

Healthcare stocks were flat to lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) inactive.AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion. Shares of Apogee Therapeutics were up nearly 47% pre-bell, while AbbVie rose 2.3%.Definium Therapeutics (DFTX) shares were up more than 60% after the company said the phase 3 Emerge trial of a single 100-microgram dose of DT120 orally disintegrating tablet in major depressive disorder met the primary endpoint, along with all key secondary efficacy endpoints.MapLight Therapeutics' (MPLT) phase 2 trial of ML-004 in autism spectrum disorder failed to meet its primary endpoint in social communication, the company said. MapLight Therapeutics stock was up 1.6% premarket.

$ABBV$APGE$DFTX$IBB$MPLT$XLV
Research

UBS Initiates MapLight Therapeutics at Buy With $48 Price Target

MapLight Therapeutics (MPLT) has an average rating of buy and mean price target of $37.90, according to analysts polled by FactSet.

$MPLT
Research

UBS Initiates MapLight Therapeutics at Buy With $48 Price Target

MapLight Therapeutics, Inc. (MPLT) has an average rating of buy and mean price target of $36.78, according to analysts polled by FactSet.

$MPLT
Insider Trading

MapLight Therapeutics Insider Sold Shares Worth $3,215,000, According to a Recent SEC Filing

Christopher A. Kroeger, Director, Chief Executive Officer, on May 18, 2026, sold 118,235 shares in MapLight Therapeutics (MPLT) for $3,215,000. Following the Form 4 filing with the SEC, Kroeger has control over a total of 1,394,094 voting common shares of the company, with 1,394,094 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000165891826000012/xslF345X05/form4-05192026_010517.xml

$MPLT

Showing 1-20 of 28

Track with the FINWIRES app suite

FolioX
FolioX
Track MPLT in your portfolio
WheelAI
WheelAI
Analyze MPLT options with the wheel strategy
StockInsider
StockInsider
See market sentiment on MPLT